Overall rank by patents
#17,534
of 50,000 tracked assignees
USPTO PatentsView assignee record - 16 granted patents across 1 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
According to USPTO PatentsView, Cascade ranks #17,534 of 50,000 tracked US assignees by granted-patent volume, with 16 patents across 1 technology areas.
USPTO PatentsView assignee plate
Corpus R17534 · US Corporation #17,534 · 16 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL
Nearest grant-volume peer: Calderco Holdings Group, Llc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Cascade Biosystems · this assignee
27 score
3D Lighting Innovati… · lowest
7 score
What this shows Cascade Biosystems, Inc. stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-RICH, TYPE-USCORP, VEL-DOWN, BOOK-FULL. Volume places it #17,534 of 50,000; Innovation Score 27.2/100 sits in the top 77% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Calderco Holdings Group, Llc (±0 grants).
Cascade Biosystems, Inc. has been granted 16 US utility patents between 2015 and 2022, placing Cascade Biosystems, Inc. at #17,534 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 1 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.5 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Cascade Biosystems, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Cascade sits between Curaden Ag (16 patents, rank #17,557) and Centricity Vision, Inc. (16 patents, rank #17,565) - the closest US assignees by grant volume. The composite Innovation Score of 27.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 6 grants, compared with 10 in the 2015–2019 window, a -40% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Cascade Biosystems, Inc.'s 19.5 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 1 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
CURADEN AG
16 patents
Calderco Holdings Group, LLC
16 patents
Calphalon Corporation
16 patents
Carbyne Ltd.
16 patents
Celator Pharmaceuticals, Inc.
16 patents
Centor Design Pty Ltd.
16 patents
Centric Software, Inc.
16 patents
Centricity Vision, Inc.
16 patents
Cascade Biosystems, Inc.
16 patents
What this shows Cascade holds 16 patents at rank #17,561, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #17,561 in granted patent volume.
Other assignees with the most granted patents in Cascade's primary technology class.
Cascade's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
27 Top 77% higher than 23% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 18.8% |
| 2016 | 2 | 12.5% |
| 2017 | 2 | 12.5% |
| 2018 | 1 | 6.3% |
| 2019 | 2 | 12.5% |
| 2020 | 1 | 6.3% |
| 2021 | 3 | 18.8% |
| 2022 | 2 | 12.5% |
Top 1 of 1 technology areas
Overall rank by patents
#17,534
of 50,000 tracked assignees
27.2 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.